BLTE Belite Bio, Inc
QT73Latest market price
154.74
+4.46+2.97%
TA
Loading chart...
Snapshot
| Index | — | P/E | — | EPS (ttm) | -2.76 | Insider Own | 2.56% | Shs Outstand | 39.85M | Perf Week | 5.03% |
| Market Cap | 6.17B | Forward P/E | 81.44 | EPS next Y | 1.90 | Insider Trans | -18.93% | Shs Float | 19.55M | Perf Month | -5.06% |
| Enterprise Value | 6.17B | PEG | — | EPS next Q | -0.79 | Short Float | 6.48% | Perf Quarter | -0.03% | ||
| Income | -102.00M | P/S | — | EPS this Y | — | Short Ratio | 6.84 | Perf Half Y | -0.07% | ||
| Sales | 0.00 | P/B | 7.94 | EPS next Y | — | ROA | -12.93% | Short Interest | 1.27M | Perf YTD | -3.26% |
| Book/sh | 19.50 | P/C | — | EPS next 5Y | — | ROE | -15.65% | 52W High | 200.00 -22.63% | Perf Year | 57.90% |
| Cash/sh | 0.00 | P/FCF | — | EPS past 3/5Y | — | ROIC | -15.28% | 52W Low | 95.29 62.39% | Perf 3Y | 316.86% |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | — | Gross Margin | 0.00% | Volatility | 4.04% 3.81% | Perf 5Y | — |
| Dividend TTM | — | EV/Sales | — | EPS Y/Y TTM | — | Oper. Margin | 0.00% | ATR (14) | 6.18 | Perf 10Y | — |
| Dividend Ex-Date | — | Quick Ratio | 33.56 | Sales Y/Y TTM | — | Profit Margin | 0.00% | RSI (14) | 50.26 | Recom | 2.00 |
| Dividend Gr. 3/5Y | — | Current Ratio | 33.56 | EPS Q/Q | -40.00% | SMA20 | 2.08% | Beta | 1.00 | Target Price | 245.83 |
| Payout | 0.00% | Debt/Eq | 0.00 | Sales Q/Q | — | SMA50 | -4.17% | Rel Volume | 1.32 | Prev Close | 150.28 |
| Employees | 41 | LT Debt/Eq | 0.00 | Earnings | Nov 09 | SMA200 | -3.51% | Avg Volume | 178.42K | Price | 154.74 |
| IPO Date | Apr 29, 2022 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 9.88% — | Net Debt/EBITDA | — | Volume | 234,874 | Change | 2.97% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Sep-09-26 | Reiterated | Mizuho | Outperform | $220 → $234 |
| Sep-08-26 | Reiterated | HC Wainwright & Co. | Buy | $214 → $245 |
| Sep-04-26 | Initiated | Canaccord | Buy | $303 |
| Aug-14-26 | Reiterated | Mizuho Securities | Outperform | $215 → $220 |
| Aug-14-26 | Reiterated | Morgan Stanley | Overweight | $191 → $206 |
| Aug-14-26 | Reiterated | Cantor Fitzgerald | Overweight | $270 |
| Aug-12-26 | Reiterated | HC Wainwright & Co. | Buy | $200 → $214 |
| May-26-26 | Reiterated | Mizuho | Outperform | $223 → $215 |
| May-22-26 | Reiterated | Truist Financial | $217 | |
| Mar-03-26 | Reiterated | Needham | $217 |
Latest News· Times ET
Oct-19-26
Oct-14-26
Oct-14-2604:00PM
Oct-01-26
Sep-28-26
Sep-17-26
Sep-17-2604:13AM
Sep-14-26
Sep-14-2609:51AM
Sep-09-26
Sep-09-2610:55AM
Sep-08-26
Sep-08-2606:00AM
Sep-04-26
Sep-03-26
Sep-03-2612:02AM
Sep-02-26
Sep-02-2605:31PM
Company
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 0 | — | — | — | |
| Cost of Goods Sold Incl. D&A | 0 | 0 | 0 | 0 | — | — | — | |
| Gross Profit | 0 | 0 | 0 | 0 | — | — | — | |
| Selling, General and Administrative Excl. Other | 60 | 39 | 10 | 7 | — | — | — | |
| Research and Development | 59 | 45 | 30 | 25 | — | — | — | |
| Other Operating Expense | 0 | 0 | 0 | 0 | — | — | — | |
| Operating Income | -119 | -84 | -40 | -32 | — | — | — | |
| Interest Expense | 0 | 0 | 0 | 0 | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 17 | 7 | 4 | 0 | — | — | — | |
| Net Income Before Taxes | -102 | -78 | -36 | -32 | — | — | — | |
| Income Taxes | 0 | 0 | 0 | 0 | — | — | — | |
| Consolidated Net Income | -102 | -78 | -36 | -32 | — | — | — | |
| Net Income From Continuing Operations | -102 | -78 | -36 | -32 | — | — | — | |
| Net Income | -102 | -78 | -36 | -32 | — | — | — | |
| EPS (Recurring) | -2.76 | -2.31 | -1.18 | -1.19 | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -2.76 | -2.31 | -1.18 | -1.19 | — | — | — | |
| EPS (Diluted) | -2.76 | -2.31 | -1.18 | -1.19 | — | — | — | |
| EBITDA | -115 | -77 | -36 | -31 | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | |
| Price To Sales Ratio | — | — | — | — | — | — | — | |
| Gross Margin | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | |
| Shares Outstanding | 40 | 34 | 31 | 27 | — | — | — | |
| Market Capitalization | 6,190 | 5,439 | 1,956 | 1,235 | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Scholl Hendrik Peter | Chief Medical Officer | Oct 01 '26 | Sale | 165.32 | 500 | 82,659 | 14,500 | Oct 05 |
| Chuang Hao-Yuan | Chief Financial Officer | Sep 08 '26 | Sale | 196.42 | 17,962 | 3,528,139 | 26,038 | Sep 09 |
| Lin Yu-Hsin | Chief Executive Officer | Sep 08 '26 | Sale | 196.56 | 26,000 | 5,110,486 | 70,134 | Sep 09 |
| Chuang Hao-Yuan | Chief Financial Officer | Sep 04 '26 | Sale | 187.64 | 49,433 | 9,275,391 | 44,000 | Sep 09 |
| Lin Yu-Hsin | Chief Executive Officer | Sep 04 '26 | Sale | 187.71 | 74,435 | 13,972,062 | 96,134 | Sep 09 |
| Chuang Hao-Yuan | Chief Financial Officer | Aug 12 '26 | Sale | 180.35 | 367 | 66,187 | 93,433 | Aug 14 |
| Lin Yu-Hsin | Chief Executive Officer | Aug 12 '26 | Sale | 180.35 | 365 | 65,827 | 170,569 | Aug 14 |
| Scholl Hendrik Peter | Chief Medical Officer | Jun 18 '26 | Sale | 145.24 | 10,000 | 1,452,436 | 15,000 | Jun 22 |
| Scholl Hendrik Peter | Chief Medical Officer | Jun 16 '26 | Sale | 140.57 | 10,000 | 1,405,729 | 25,000 | Jun 17 |
| MATA NATHAN L. | Chief Scientific Officer | May 07 '26 | Sale | 153.21 | 666 | 102,039 | 0 | May 08 |
| MATA NATHAN L. | Chief Scientific Officer | May 06 '26 | Sale | 153.84 | 1,000 | 153,840 | 666 | May 07 |
| MATA NATHAN L. | Chief Scientific Officer | May 05 '26 | Sale | 155.50 | 1,000 | 155,503 | 1,666 | May 06 |
| MATA NATHAN L. | Chief Scientific Officer | May 04 '26 | Sale | 155.64 | 1,000 | 155,635 | 2,666 | May 05 |
| MATA NATHAN L. | Chief Scientific Officer | May 01 '26 | Sale | 155.78 | 1,000 | 155,778 | 3,666 | May 04 |
| MATA NATHAN L. | Chief Scientific Officer | Apr 30 '26 | Sale | 156.97 | 1,000 | 156,972 | 4,666 | May 01 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.